All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

An expert panel hosted by

The Lymphoma Hub logo and the Multiple Myeloma Hub logo

Sequencing immune-based therapies in B-cell malignancies

with Ulric Jäger, Sagar Lonial, and Krina Patel

Saturday, June 15 | 18:00-19:30 CEST

Register now

This independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.


The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

How to identify and mitigate neurologic AEs when treating with CAR-T and T-cell engagers?

Bookmark this article

During the EHA2021 Virtual Congress, the Multiple Myeloma Hub spoke with Hermann Einsele, Julius-Maximilians-Universität Würzburg, Würzburg, DE. We asked, How do you identify and mitigate neurologic adverse events (AEs) when treating with chimeric antigen receptor (CAR)-T and T-cell engagers?

In this video, Einsele discusses the identification, management, and prophylaxis of severe neurologic toxicities associated with treatment with CAR-T and T-cell engagers.



Subscribe to get the best content related to multiple myeloma delivered to your inbox